Prevalence and Clinicopathologic Association of Hashimoto’s Thyroiditis in Papillary Thyroid Cancer after Radioiodine (I-131) Treatment
Article Sidebar
Main Article Content
Abstract
Background: Some of the patients with papillary thyroid cancer (PTC) have coexistence of Hashimoto’s thyroiditis or chronic lymphocytic thyroiditis (CLT). Association between CLT, clinicopathologic factors and
response to radioiodine (I-131) treatment remain unclear.
Objective: To determine the prevalence of CLT in PTC and the association of coexistent CLT and the clinicopathological features of PTC.
Materials and methods: A cross-sectional analytical study was conducted among 277 patients who underwent thyroidectomy and I-131 treatment in Surat Thani Hospital between January 2009 and May 2016.
Clinical data, pathological characteristics and response to I-131 treatment were compared between the two groups according to the presence or absence of CLT. The association between CLT and clinicopathologic
factors were analyzed by logistic regression analysis.
Results: The mean age of patients was 42.9±13.0 years (range 19-84). Most of them were female (n=250, 90.2%).CLT was present in 65 cases (23.5%). Excellent response to I-131 in the CLT group was higher than the non-CLT group (80.0% vs 66.5%, p=0.038) and associated with the presence of CLT by univariate logistic regression (OR 2.01, 95%CI 1.03-3.94, p=0.041). Using multivariate logistic regression, factors associated with the presence of CLT were female (adjusted OR 10.59, 95%CI 1.31-85.65, p=0.027); tumor size ≤ 1 cm (adjusted OR 1.86, 95%CI 1.06-1.93, p=0.041); extrathyroidal extension (adjusted OR 0.25, 95%CI 0.08-0.77, p=0.016); and capsular invasion (adjusted OR 0.29, 95%CI 0.09-0.96, p=0.042).
Conclusion: The prevalence of CLT in PTC was 23.5%. CLT was associated with females and tumor sizes ≤ 1 cm. There was a tendency for excellent responses to radioiodine treatment in the patients with PTC and
Article Details
บทความที่ส่งมาลงพิมพ์ต้องไม่เคยพิมพ์หรือกำลังได้รับการพิจารณาตีพิมพ์ในวารสารอื่น เนื้อหาในบทความต้องเป็นผลงานของผู้นิพนธ์เอง ไม่ได้ลอกเลียนหรือตัดทอนจากบทความอื่น โดยไม่ได้รับอนุญาตหรือไม่ได้อ้างอิงอย่างเหมาะสม การแก้ไขหรือให้ข้อมูลเพิ่มเติมแก่กองบรรณาธิการ จะต้องเสร็จสิ้นเป็นที่เรียบร้อยก่อนจะได้รับพิจารณาตีพิมพ์ และบทความที่ตีพิมพ์แล้วเป็นสมบัติ ของลำปางเวชสาร
References
Jung CK, Little MP, Lubin JH, Brenner AV, Wells Jr SA, Sigurdson AJ, et al. The increase in thyroid cancer
incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276-85.
Sriplung H. Thyroid. In: Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungrung K, Sangrajrang S, et al., Cancer in Thailand: Vol VIII, 2010-2012. Bangkok: National Cancer Instritute, Thailand; 2015. p. 64-6.
Greenspan BS. Radioiodine treatment of welldifferentiated thyroid cancer: balancing risks and benefits. J Clin Oncol. 2018;36(18):1785-7.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid
Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: American Thyroid Association (ATA) Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009;19(11):1167-214.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH,
T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and
Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99.
Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC. Hashimoto’s thyroiditis pathology and risk for thyroid cancer. Thyroid. 2014;24(7):1107-14.
Borowczyk M, Janicki A, Dworacki G, Szczepanek-Parulska E, Danieluk M, Barnett J, et al. Decreased staging of differentiated thyroid cancer in patients with chronic lymphocytic thyroiditis. J Endocrinol Invest. 2019;42(1):45-52.
Babli S, Payne RJ, Mitmaker E, Rivera J. Effects of chronic lymphocytic thyroiditis on the
clinicopathological features of papillary thyroid cancer. Eur Thyroid J. 2018;7(2):95-101.
Noureldine SI, Tufano RP. Association of Hashimoto’s thyroiditis and thyroid cancer. Curr Opin Oncol. 2015;27(1):21-5.
Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol. 2013;168(3):343-9.
Del Rio P, Cataldo S, Sommaruga L, Concione L, Arcuri MF, Sianesi M. The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer? Minerva Endocrinol. 2008;33(1):1-5.
Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid. 1998;8(3):197-202.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Thyroid. 2016;26(1):1-133.
Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid. 2013;23(10):1211-25.
Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer. 2018;25(3):7-11.
Vita R, Ieni A, Tuccari G, Benvenga S. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord. 2018;19(4):301-9.
Uhliarova B, Hajtman A. Hashimoto’s thyroiditis - an independent risk factor for papillary carcinoma.
Braz J Otorhinolaryngol. 2018;84(6):729-35.
Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab. 1995;80(12):3421-4.
Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955;70(2):291-7.
Moon S, Chung HS, Yu JM, Yoo HJ, Park JH, Kim DS, et al. Associations between Hashimoto Thyroiditis
and clinical outcomes of papillary thyroid cancer: a meta-analysis of observational studies. Endocrinol Metab (Seoul). 2018;33(4):473-84.
Myshunina TM, Guda BD, Bolgov MY, Mikhailenko NI, Tronko ND. Differentiated thyroid carcinomas
associated with chronic thyroiditis: biological and clinical properties. Exp Oncol. 2018;40(2):128-31.
Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked?. Trends Endocrinol Metab. 2014;25(12):656-64.
Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis. Am J Cancer Res. 2012;2(3):286-97.